ID   KPCD3_HUMAN             Reviewed;         890 AA.
AC   O94806; D6W587; Q53TR7; Q8NEL8;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   12-OCT-2022, entry version 197.
DE   RecName: Full=Serine/threonine-protein kinase D3;
DE            EC=2.7.11.13;
DE   AltName: Full=Protein kinase C nu type;
DE   AltName: Full=Protein kinase EPK2;
DE   AltName: Full=nPKC-nu;
GN   Name=PRKD3; Synonyms=EPK2, PRKCN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Embryo;
RX   PubMed=10231560; DOI=10.1016/s0167-4889(99)00040-3;
RA   Hayashi A., Seki N., Hattori A., Kozuma S., Saito T.;
RT   "PKCnu, a new member of the protein kinase C family, composes a fourth
RT   subfamily with PKCmu.";
RL   Biochim. Biophys. Acta 1450:99-106(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS THR-128
RP   AND ARG-546.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   ACTIVITY REGULATION, SUBCELLULAR LOCATION, PHORBOL-ESTER BINDING, AND
RP   MUTAGENESIS OF THR-156; TYR-158; PRO-165; THR-166; TYR-170; PRO-282 AND
RP   LYS-293.
RX   PubMed=18076381; DOI=10.1042/bj20071334;
RA   Chen J., Deng F., Li J., Wang Q.J.;
RT   "Selective binding of phorbol esters and diacylglycerol by individual C1
RT   domains of the PKD family.";
RL   Biochem. J. 411:333-342(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; SER-27; SER-37; SER-41;
RP   SER-213; SER-216; SER-364 AND THR-535, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41; SER-44 AND
RP   SER-364, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41; SER-213; SER-216;
RP   SER-364 AND THR-535, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-41 AND SER-44, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-44 AND SER-364, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   STRUCTURE BY NMR OF 414-532.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the PH domain of protein kinase C, nu type from
RT   human.";
RL   Submitted (JAN-2007) to the PDB data bank.
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-716.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Converts transient diacylglycerol (DAG) signals into
CC       prolonged physiological effects, downstream of PKC. Involved in
CC       resistance to oxidative stress (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by DAG and phorbol esters. Phorbol-
CC       ester/DAG-type domains 1 and 2 bind both DAG and phorbol ester with
CC       high affinity and mediate translocation to the cell membrane.
CC       Autophosphorylation of Ser-735 and phosphorylation of Ser-731 by PKC
CC       relieves auto-inhibition by the PH domain.
CC       {ECO:0000269|PubMed:18076381}.
CC   -!- INTERACTION:
CC       O94806; P63027: VAMP2; NbExp=7; IntAct=EBI-1255366, EBI-520113;
CC       O94806-2; Q9UGP5-2: POLL; NbExp=3; IntAct=EBI-13337369, EBI-10320765;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18076381}. Membrane
CC       {ECO:0000269|PubMed:18076381}. Note=Translocation to the cell membrane
CC       is required for kinase activation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O94806-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O94806-2; Sequence=VSP_029405, VSP_029406;
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. PKD subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB015982; BAA36514.1; -; mRNA.
DR   EMBL; AC007390; AAY14817.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00398.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00399.1; -; Genomic_DNA.
DR   EMBL; BC030706; AAH30706.1; -; mRNA.
DR   CCDS; CCDS1789.1; -. [O94806-1]
DR   RefSeq; NP_005804.1; NM_005813.4. [O94806-1]
DR   RefSeq; XP_005264294.1; XM_005264237.3. [O94806-1]
DR   PDB; 2D9Z; NMR; -; A=417-532.
DR   PDBsum; 2D9Z; -.
DR   AlphaFoldDB; O94806; -.
DR   BMRB; O94806; -.
DR   SMR; O94806; -.
DR   BioGRID; 117199; 31.
DR   IntAct; O94806; 26.
DR   MINT; O94806; -.
DR   STRING; 9606.ENSP00000368356; -.
DR   BindingDB; O94806; -.
DR   ChEMBL; CHEMBL2595; -.
DR   DrugCentral; O94806; -.
DR   GuidetoPHARMACOLOGY; 2174; -.
DR   iPTMnet; O94806; -.
DR   PhosphoSitePlus; O94806; -.
DR   SwissPalm; O94806; -.
DR   BioMuta; PRKD3; -.
DR   EPD; O94806; -.
DR   jPOST; O94806; -.
DR   MassIVE; O94806; -.
DR   MaxQB; O94806; -.
DR   PaxDb; O94806; -.
DR   PeptideAtlas; O94806; -.
DR   PRIDE; O94806; -.
DR   ProteomicsDB; 50446; -. [O94806-1]
DR   ProteomicsDB; 50447; -. [O94806-2]
DR   Antibodypedia; 14569; 427 antibodies from 36 providers.
DR   DNASU; 23683; -.
DR   Ensembl; ENST00000234179.8; ENSP00000234179.2; ENSG00000115825.11. [O94806-1]
DR   Ensembl; ENST00000379066.5; ENSP00000368356.1; ENSG00000115825.11. [O94806-1]
DR   GeneID; 23683; -.
DR   KEGG; hsa:23683; -.
DR   MANE-Select; ENST00000234179.8; ENSP00000234179.2; NM_005813.6; NP_005804.1.
DR   UCSC; uc002rqd.4; human. [O94806-1]
DR   CTD; 23683; -.
DR   DisGeNET; 23683; -.
DR   GeneCards; PRKD3; -.
DR   HGNC; HGNC:9408; PRKD3.
DR   HPA; ENSG00000115825; Low tissue specificity.
DR   MIM; 607077; gene.
DR   neXtProt; NX_O94806; -.
DR   OpenTargets; ENSG00000115825; -.
DR   PharmGKB; PA33772; -.
DR   VEuPathDB; HostDB:ENSG00000115825; -.
DR   eggNOG; KOG4236; Eukaryota.
DR   GeneTree; ENSGT00950000183024; -.
DR   HOGENOM; CLU_009772_1_0_1; -.
DR   InParanoid; O94806; -.
DR   OMA; VCSVVYQ; -.
DR   OrthoDB; 367841at2759; -.
DR   PhylomeDB; O94806; -.
DR   TreeFam; TF314320; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; O94806; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   SignaLink; O94806; -.
DR   SIGNOR; O94806; -.
DR   BioGRID-ORCS; 23683; 14 hits in 1113 CRISPR screens.
DR   ChiTaRS; PRKD3; human.
DR   EvolutionaryTrace; O94806; -.
DR   GeneWiki; PRKD3; -.
DR   GenomeRNAi; 23683; -.
DR   Pharos; O94806; Tchem.
DR   PRO; PR:O94806; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O94806; protein.
DR   Bgee; ENSG00000115825; Expressed in calcaneal tendon and 196 other tissues.
DR   ExpressionAtlas; O94806; baseline and differential.
DR   Genevisible; O94806; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0016301; F:kinase activity; IDA:CACAO.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:Reactome.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0089700; P:protein kinase D signaling; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015727; Protein_Kinase_C_mu-related.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22968; PTHR22968; 1.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000552; PKC_mu_nu_D2; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 2.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transferase;
KW   Zinc; Zinc-finger.
FT   CHAIN           1..890
FT                   /note="Serine/threonine-protein kinase D3"
FT                   /id="PRO_0000055717"
FT   DOMAIN          416..532
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          576..832
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         154..204
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         271..321
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   REGION          332..371
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        332..351
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        352..371
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        699
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         582..590
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         605
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         6
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         27
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         44
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         213
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         216
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         364
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         426
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         457
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   MOD_RES         535
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         539
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K1Y2"
FT   MOD_RES         731
FT                   /note="Phosphoserine; by PKC"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         735
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q15139"
FT   MOD_RES         742
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BZL6"
FT   VAR_SEQ         595..611
FT                   /note="HRKTGRDVAIKVIDKMR -> QLQPFAYCTHYFKNWKM (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_029405"
FT   VAR_SEQ         612..890
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_029406"
FT   VARIANT         42
FT                   /note="N -> D (in dbSNP:rs11896614)"
FT                   /id="VAR_037147"
FT   VARIANT         128
FT                   /note="A -> T (in dbSNP:rs17852819)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_037148"
FT   VARIANT         225
FT                   /note="P -> S (in dbSNP:rs34280934)"
FT                   /id="VAR_050561"
FT   VARIANT         445
FT                   /note="L -> I (in dbSNP:rs55912911)"
FT                   /id="VAR_061532"
FT   VARIANT         546
FT                   /note="Q -> R (in dbSNP:rs17856887)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_037149"
FT   VARIANT         716
FT                   /note="V -> M (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042336"
FT   MUTAGEN         156
FT                   /note="T->A: Slight loss in ability to bind DAG and
FT                   phorbol-ester; when associated with F-158."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         158
FT                   /note="Y->F: Slight loss in ability to bind DAG and
FT                   phorbol-ester; when associated with A-156."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         165
FT                   /note="P->G: No effect on ability to bind phorbol ester,
FT                   loss of ability to bind DAG, reduced DAG-induced membrane
FT                   translocation."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         166
FT                   /note="T->A: Slight loss in ability to bind DAG and
FT                   phorbol-ester."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         170
FT                   /note="Y->F: Slight loss in ability to bind DAG and
FT                   phorbol-ester."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         282
FT                   /note="P->G: No effect on ability to bind phorbol ester,
FT                   increase in ability to bind DAG."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   MUTAGEN         284
FT                   /note="I->V: Slight increase in ability to bind DAG, no
FT                   effect on phorbol-ester binding."
FT   MUTAGEN         293
FT                   /note="K->W: Increased ability to bind DAG, no effect on
FT                   phorbol-ester binding."
FT                   /evidence="ECO:0000269|PubMed:18076381"
FT   STRAND          417..429
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   STRAND          434..443
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   STRAND          445..449
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   TURN            462..464
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   STRAND          477..479
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   STRAND          485..489
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   STRAND          494..497
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   TURN            508..514
FT                   /evidence="ECO:0007829|PDB:2D9Z"
FT   HELIX           517..532
FT                   /evidence="ECO:0007829|PDB:2D9Z"
SQ   SEQUENCE   890 AA;  100471 MW;  66D5E7E7235064F5 CRC64;
     MSANNSPPSA QKSVLPTAIP AVLPAASPCS SPKTGLSARL SNGSFSAPSL TNSRGSVHTV
     SFLLQIGLTR ESVTIEAQEL SLSAVKDLVC SIVYQKFPEC GFFGMYDKIL LFRHDMNSEN
     ILQLITSADE IHEGDLVEVV LSALATVEDF QIRPHTLYVH SYKAPTFCDY CGEMLWGLVR
     QGLKCEGCGL NYHKRCAFKI PNNCSGVRKR RLSNVSLPGP GLSVPRPLQP EYVALPSEES
     HVHQEPSKRI PSWSGRPIWM EKMVMCRVKV PHTFAVHSYT RPTICQYCKR LLKGLFRQGM
     QCKDCKFNCH KRCASKVPRD CLGEVTFNGE PSSLGTDTDI PMDIDNNDIN SDSSRGLDDT
     EEPSPPEDKM FFLDPSDLDV ERDEEAVKTI SPSTSNNIPL MRVVQSIKHT KRKSSTMVKE
     GWMVHYTSRD NLRKRHYWRL DSKCLTLFQN ESGSKYYKEI PLSEILRISS PRDFTNISQG
     SNPHCFEIIT DTMVYFVGEN NGDSSHNPVL AATGVGLDVA QSWEKAIRQA LMPVTPQASV
     CTSPGQGKDH KDLSTSISVS NCQIQENVDI STVYQIFADE VLGSGQFGIV YGGKHRKTGR
     DVAIKVIDKM RFPTKQESQL RNEVAILQNL HHPGIVNLEC MFETPERVFV VMEKLHGDML
     EMILSSEKSR LPERITKFMV TQILVALRNL HFKNIVHCDL KPENVLLASA EPFPQVKLCD
     FGFARIIGEK SFRRSVVGTP AYLAPEVLRS KGYNRSLDMW SVGVIIYVSL SGTFPFNEDE
     DINDQIQNAA FMYPPNPWRE ISGEAIDLIN NLLQVKMRKR YSVDKSLSHP WLQDYQTWLD
     LREFETRIGE RYITHESDDA RWEIHAYTHN LVYPKHFIMA PNPDDMEEDP
//
